Navigation Links
StoredIQ Shares Expertise at IQPC's eDiscovery Pharma, Biotech and Medical Device Conference
Date:9/10/2009

AUSTIN, Texas, Sept. 10 /PRNewswire/ --

WHO: Panel of leading eDiscovery experts including Dan Junk, Esq., VP of Business Development, StoredIQ

WHEN: Tuesday, September 15th

9:50 a.m. ET

WHERE: IQPC's 4th Conference on eDiscovery for Pharma, Biotech & Medical Device Industries

The Hub Cira Centre -- Philadelphia, PA

TOPIC: Cost-Benefit Analysis of In-house eDiscovery Tools vs. Outsourcing Help

DESCRIPTION:

Product liability lawsuits, patent disputes, class action claims, and regulatory investigations continue to challenge healthcare companies. IQPC's 4th Conference on eDiscovery for Pharma, Biotech & Medical Device Industries, focuses on eDiscovery and retention specifically for the highly regulated and litigious drug and medical device markets.

Addressing the cost and benefits of bringing eDiscovery in-house, StoredIQ's Vice President of Business Development, will take part in a panel discussion which includes Dr. Ellen Voorhees, TREC Project Manager from the National Institute of Standards and Technology and Huong Nyugen, Director of Intellectual Property from Impax Laboratories. Panel discussions will center on:

  • Examining how the eDiscovery tools and trends have changed and how they are evolving
  • Persuading the executive management the importance of eDiscovery readiness via a comprehensive cost-benefit analysis
  • Discussing impact of technology that is evolving faster than the laws and identifying areas of increasing importance when vetting eDiscovery technolog
    '/>"/>

SOURCE StoredIQ
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
3. Neuralstem Shares Accepted for Trading on Amex(R)
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
6. Essilor Cancels 700,000 Shares
7. Helix BioPharma announces $16.9 million private placement of common shares
8. Helix BioPharma closes $16.9 million private placement of common shares
9. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
10. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
11. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the leading ... methodologies relating to cannabis, today announced that it has ... from an existing stockholder of the Company. , ... from one of our existing stockholders,” stated Mark ... help accelerate our planned expansions into the Connecticut and ...
(Date:11/22/2014)... 2014 The “Chiral Chromatography Columns ... Material (Metal, Glass, Plastic), by Application [GC, LC ... Forecast to 2018” analyses and studies the major ... America, Europe, Asia, and Rest of the World. ... figures spread through 135 pages and in-depth TOC ...
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... The science of light and how it ... than 200 primary students in a traveling program organized ... Otago Physics Department and funded by an SPIE ... the university’s OSA/SPIE Student Chapter visited six primary schools ... from small, rural schools hands-on lessons in optics and ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3
... , MALVERN, Pa. and WALTHAM, Mass., Nov. ... find that the leading driver of antibiotic selection in ... and gram-negative pathogens. Due to the variety of organisms ... that they look primarily for agents that provide appropriate ...
... , MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. ... a randomized Phase 2B study of AEG35156, a targeted ... , The study, entitled "An Open-Label Randomized Phase 2 ... AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin ...
... ... Consortium (IGSC) to Coordinate Best Practices in Risk Reduction ,Five Member Companies Represent ... ... leading gene synthesis companies today announced agreement that they will apply a common screening ...
Cached Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
(Date:11/3/2014)... study published in this month,s Proceedings ... activity of a recently discovered communication molecule of the ... been known to limit inflammation and the current study ... inhibits the ability of the immune system to recognize ... underlies IL-37,s effect on the immune system now allows ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... reprogrammed stem cells from a key organ in the immune ... regeneration. Their research shows that it is possible to ... genetic modification. Researchers, who used rat models, grew ... our immune systems in the laboratory using conditions for ...
... destroys brain cells and their connections (called synapses), causing ... hobbies and daily life. Symptoms can be alleviated, in ... States as Namenda), which is currently FDA-approved to treat ... Stuart A. Lipton, M.D., Ph.D., Director of the Del ...
... Tech College of Engineering researchers have received a $60,000 ... occurring microbes can best be used to eat away ... Their choice of weapon: Geometry. Fueled by oxygen, ... of crude oil without the use of additional chemicals. ...
Cached Biology News:Stem cell versatility could help tissue regeneration 2Study explains why Alzheimer's drug is both safe and effective 2Does the shape of crude oil remnants impact rate of biodegradation? 2Does the shape of crude oil remnants impact rate of biodegradation? 3
...
Mouse polyclonal antibody raised against a partial recombinant PREB. NCBI Entrez Gene ID = 10113...
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
... used to test the crossreactivity of an ... are commonly used as blocking reagents or ... 19 different protein preparations on a nitrocellulose ... species specificity, QC of purified antibodies, selection ...
Biology Products: